TECH Valuation

Bio-Techne Corp

Add to Watchlist

Advanced Chart

53.860

+0.26(0.485%)1D

Overview
Forecast
Valuation
Earnings

TECH Relative Valuation

TECH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TECH is overvalued; if below, it's undervalued.

Historical Valuation

Bio-Techne Corp (TECH) is now in the Undervalued zone, suggesting that its current forward PE ratio of 26.66 is considered Undervalued compared with the five-year average of 43.05. The fair price of Bio-Techne Corp (TECH) is between 68.13 to 101.49 according to relative valuation methord. Compared to the current price of 53.86 USD , Bio-Techne Corp is Undervalued By 20.95%.

Relative Value

Fair Zone

68.13-101.49

Current Price：53.86

20.95%

Undervalued

26.66

Trailing

Forward

19.69

EV/EBITDA

Bio-Techne Corp. (TECH) has a current EV/EBITDA of 19.69. The 5-year average EV/EBITDA is 30.24. The thresholds are as follows: Strongly Undervalued below 16.67, Undervalued between 16.67 and 23.45, Fairly Valued between 37.02 and 23.45, Overvalued between 37.02 and 43.80, and Strongly Overvalued above 43.80. The current Forward EV/EBITDA of 19.69 falls within the Undervalued range.

21.55

EV/EBIT

Bio-Techne Corp. (TECH) has a current EV/EBIT of 21.55. The 5-year average EV/EBIT is 32.57. The thresholds are as follows: Strongly Undervalued below 18.35, Undervalued between 18.35 and 25.46, Fairly Valued between 39.68 and 25.46, Overvalued between 39.68 and 46.79, and Strongly Overvalued above 46.79. The current Forward EV/EBIT of 21.55 falls within the Undervalued range.

6.76

Bio-Techne Corp. (TECH) has a current PS of 6.76. The 5-year average PS is 11.40. The thresholds are as follows: Strongly Undervalued below 5.19, Undervalued between 5.19 and 8.29, Fairly Valued between 14.50 and 8.29, Overvalued between 14.50 and 17.61, and Strongly Overvalued above 17.61. The current Forward PS of 6.76 falls within the Undervalued range.

24.79

P/OCF

Bio-Techne Corp. (TECH) has a current P/OCF of 24.79. The 5-year average P/OCF is 37.78. The thresholds are as follows: Strongly Undervalued below 18.73, Undervalued between 18.73 and 28.26, Fairly Valued between 47.30 and 28.26, Overvalued between 47.30 and 56.82, and Strongly Overvalued above 56.82. The current Forward P/OCF of 24.79 falls within the Undervalued range.

27.14

P/FCF

Bio-Techne Corp. (TECH) has a current P/FCF of 27.14. The 5-year average P/FCF is 43.42. The thresholds are as follows: Strongly Undervalued below 21.67, Undervalued between 21.67 and 32.55, Fairly Valued between 54.29 and 32.55, Overvalued between 54.29 and 65.16, and Strongly Overvalued above 65.16. The current Forward P/FCF of 27.14 falls within the Undervalued range.

Bio-Techne Corp (TECH) has a current Price-to-Book (P/B) ratio of 4.33. Compared to its 3-year average P/B ratio of 5.81 , the current P/B ratio is approximately -25.46% higher. Relative to its 5-year average P/B ratio of 7.37, the current P/B ratio is about -41.29% higher. Bio-Techne Corp (TECH) has a Forward Free Cash Flow (FCF) yield of approximately 3.05%. Compared to its 3-year average FCF yield of 2.17%, the current FCF yield is approximately 40.68% lower. Relative to its 5-year average FCF yield of 1.97% , the current FCF yield is about 55.24% lower.

4.33

P/B

Median3y

5.81

Median5y

7.37

3.05

FCF Yield

Median3y

2.17

Median5y

1.97

Competitors Valuation Multiple

The average P/S ratio for TECH's competitors is 128.24, providing a benchmark for relative valuation. Bio-Techne Corp Corp (TECH) exhibits a P/S ratio of 6.76, which is -94.73% above the industry average. Given its robust revenue growth of 3.55%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Elanco Animal Health Inc

Halozyme Therapeutics Inc

Avidity Biosciences Inc

Telix Pharmaceuticals Ltd

4.99

7.81B

Performance Decomposition

Market capitalization of TECH decreased by 27.48% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 55.21 to 116.52.

The secondary factor is the Revenue Growth, contributed 3.55%to the performance.

Overall, the performance of TECH in the past 1 year is driven by P/E Change. Which is more unsustainable.

3.55%

306.10M → 316.96M

Revenue Growth

-142.08%

13.26 → -5.58

Margin Expansion

111.05%

55.21 → 116.52

P/E Change

-27.48%